-
Publication Venue For
-
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial..
22:494-504.
2023
-
Carpal tunnel syndrome: updated evidence and new questions..
22:255-267.
2023
-
Prediction of autism in infants: progress and challenges..
22:244-254.
2023
-
Advancing research in autoimmune neuromuscular disorders..
21:108-110.
2022
-
Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders..
21:176-188.
2022
-
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial..
20:1012-1026.
2021
-
Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial..
20:1027-1037.
2021
-
Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019..
20:795-820.
2021
-
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial..
20:821-831.
2021
-
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial..
20:537-547.
2021
-
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial..
20:284-293.
2021
-
Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial..
20:98-106.
2021
-
COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)..
19:970-971.
2020
-
Introducing the Society of Black Neurologists..
19:892-893.
2020
-
Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study..
18:953-961.
2019
-
Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis..
18:666-673.
2019
-
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial..
18:428-438.
2019
-
Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..
18:459-480.
2019
-
Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..
18:376-393.
2019
-
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial..
18:259-268.
2019
-
Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..
18:88-106.
2019
-
Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016..
18:56-87.
2019
-
Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial..
17:587-596.
2018
-
Intravenous versus subcutaneous immunoglobulin - Authors' reply..
17:393-394.
2018
-
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management..
17:347-361.
2018
-
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management..
17:251-267.
2018
-
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial..
17:35-46.
2018
-
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study..
16:976-986.
2017
-
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015..
16:877-897.
2017
-
Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis..
16:898-907.
2017
-
Diagnosis and treatment of carpal tunnel syndrome - Authors' response..
16:263-264.
2017
-
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial..
16:189-199.
2017
-
Ultra-rare genetic variation in common epilepsies: a case-control sequencing study..
16:135-143.
2017
-
Carpal tunnel syndrome: clinical features, diagnosis, and management..
15:1273-1284.
2016
-
Clarity in EEG diagnosis of non-convulsive status epilepticus..
15:1001-1003.
2016
-
Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies..
15:695-707.
2016
-
Accelerating stem cell trials for Alzheimer's disease..
15:219-230.
2016
-
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial..
14:795-803.
2015
-
Neuroinflammation in Alzheimer's disease..
14:388-405.
2015
-
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial..
14:39-47.
2015
-
Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies..
13:893-903.
2014
-
Distinct neurological disorders with ATP1A3 mutations..
13:503-514.
2014
-
Neurological complications of cardiac surgery..
13:490-502.
2014
-
Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial..
13:461-471.
2014
-
Embolic strokes of undetermined source: the case for a new clinical construct..
13:429-438.
2014
-
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study..
11:669-678.
2012
-
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial..
11:503-511.
2012
-
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF..
11:315-322.
2012
-
Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial..
11:131-139.
2012
-
Novel platelet antiaggregants and the changing landscape of stroke prevention..
10:678-680.
2011
-
Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial..
10:140-147.
2011
-
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial..
9:1164-1172.
2010
-
Neurological complications of systemic cancer..
9:1214-1227.
2010
-
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care..
9:177-189.
2010
-
Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen..
9:67-76.
2010
-
Lifeline. An interview of Kate Bushby..
9:37.
2010